A prospective study reported that longitudinal increases in circulating Granzyme B and activated cytotoxic lymphocytes track response and survival during second-line nivolumab in advanced non-small cell lung cancer. The work positions Granzyme B dynamics as a measurable signal associated with therapeutic activity over time. The study emphasizes repeatable monitoring rather than a single baseline biomarker, aligning with the broader shift toward dynamic treatment response markers in immunotherapy. The results suggest that immune activation can be observed in the periphery as therapy progresses. If validated, this type of pharmacodynamic readout could support earlier identification of responders and inform combination or sequencing decisions in metastatic settings where outcomes vary widely.
Get the Daily Brief